Alector, Inc.
NASDAQ:ALECBiotechnology
+$0.08 today
- Market cap
- $382.61M
- Beta
- 0.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.13
Volume 2.13M
Average 0.65M
ALEC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Alector, Inc.NASDAQ: ALEC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.91M fell 65.2% year over year, behind the -43.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 40.0% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.
Context
- Stock-based compensation amounted to 126.7% of revenue in FY2025, up 87.4 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -65.2% toward the trailing-twelve-month pace of -43.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 26.66M USD
- Year-over-year change
- -32.4%
- 4-year CAGR
- -10.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.66M | -32.4% |
| FY2024 | 2024-12-31 | 39.46M | -7.8% |
| FY2023 | 2023-12-31 | 42.8M | -7.3% |
| FY2022 | 2022-12-31 | 46.15M | +13.1% |
| FY2021 | 2021-12-31 | 40.79M | — |
Stock-Based Compensation vs competitors
How ALEC compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -43.4% is the 8th highest of 9, against a peer median of -4.9%.
- Stock-based compensation amounts to 115.2% of revenue for ALEC, versus a peer median of 186.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.69M USD | +218.3% | +20.9% | — | |
| LTM Mar 2026 | $21.47M USD | -43.3% | -31.8% | 340.0% | |
| LTM Mar 2026 | $21.22M USD | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $9.77M USD | +1.5% | +47.6% | — | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M USD | +20.1% | +23.4% | 33.0% |
| Peer median (excluding ALEC) | — | -4.9% | +12.1% | 186.5% | |
Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.33M) | (133.31M) | (130.39M) | (119.05M) | (142.93M) |
| Depreciation & Amortization | 8.32M | 8.47M | 8.85M | 8.84M | (861K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.79M | 46.15M | 42.8M | 39.46M | 26.66M |
| Change in Working Capital | 283.68M | 59.53M | (90.15M) | (146.99M) | (74.06M) |
| Accounts Receivables | (7.39M) | 4.8M | 2.59M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.92M | (572K) | (377K) | (1.44M) | (524K) |
| Other Working Capital | 289.16M | 55.29M | (92.36M) | (145.55M) | (73.53M) |
| Other Non-Cash Items | 2.1M | (1.16M) | (15.27M) | (12.17M) | 7.16M |
| Operating Cash Flow | 298.55M | (20.33M) | (184.16M) | (229.91M) | (184.03M) |
| Capital Expenditures | (3.25M) | (4.12M) | (2.38M) | (1.26M) | (41K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (343.4M) | (556.9M) | (551.73M) | (467.74M) | (271.88M) |
| Sales of Investments | 296.99M | 402M | 656.03M | 576.13M | 468.52M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (49.66M) | (159.01M) | 101.92M | 107.13M | 196.6M |
| Debt Repayment | 0 | 0 | 0 | 9.39M | 0 |
| Common Stock Issued | 0 | 4.51M | 2.55M | 71.11M | 20M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 30.3M | 0 | 0 | 1.04M | 217K |
| Financing Cash Flow | 30.3M | 4.51M | 2.55M | 81.54M | 20.22M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 279.18M | (174.83M) | (79.69M) | (41.23M) | 32.78M |
| Free Cash Flow | 295.3M | (24.45M) | (186.54M) | (231.16M) | (184.07M) |
Alector, Inc.
NASDAQ:ALEC
Intrinsic Alpha fair value
Locked
Current Price
$2.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.